SecBot SecBot
SC 13G/A ·Filed Nov 13, 2026

XLO

Xilio Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3d 5h ago SEC0001104659-26-127419
Passive stake amendment
Actionable Insight • Neutral

Monitor for any future conversion of this passive 13G filing to a 13D (activist) filing, which would signal a change in intent. The stake is at the 9.99% cap, limiting further accumulation without exceeding the beneficial ownership limitation.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Coastlands Capital LP filed an amended Schedule 13G disclosing a 9.99% passive beneficial ownership stake in Xilio Therapeutics, holding 731,573 shares (including pre-funded warrant shares) as of September 30, 2026. The amendment reflects a reverse stock split and recent transactions, with the stake remaining at the 9.99% beneficial ownership limitation cap.

Key Financial Metrics

Stake
9.99%
Investor
Coastlands Capital LP
Investor Type
hedge fund

Key Facts

  • Coastlands Capital LP and related entities hold 731,573 shares of Xilio common stock, representing 9.99% beneficial ownership.
  • The stake includes shares issuable upon exercise of pre-funded warrants, subject to a 9.99% beneficial ownership limitation.
  • The filing is an amendment to reflect a reverse stock split and transactions in common stock.
  • The stake is passive, with no intent to change or influence control of the issuer.
  • The filing date is November 13, 2026, with ownership as of September 30, 2026.

Financial Impact

9.99% beneficial ownership stake, valued at approximately $6.0M based on $60M market cap.

ownership percentage

Risk Factors

  • The filing does not disclose the exact number of shares held outright versus those issuable upon warrant exercise, creating some ambiguity about actual economic exposure.
  • A passive filing at the 9.99% cap may precede a shift to active engagement if the investor's thesis changes.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001104659-26-127419
Document: 0001104659-26-127419-index.html0001104659-26-127419
Document: 0001104659-26-127419.txt0001104659-26-127419

Track record

16 reports on XLO

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +19.92% at T+60 after the May 12, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $7.70 Now $7.70 −0.00% settles Nov 24
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Viewing Entry $7.96 Now $7.70 −3.27% settles Nov 23
  3. Nov 12, 20264d ago SC 13G Neutral 4/10 Entry $8.24 Now $7.70 −6.55% settles Nov 19
  4. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $8.53 Now $7.70 −9.73% settles Nov 17
  5. Oct 26, 202621d ago Press Release Neutral 4/10 Entry $7.31 to $8.03 Now $7.70 +5.34% ▲ +9.85% +11.11% vs SPY
  6. Aug 12, 202613w ago 8-K Bullish 7/10 No price data
  7. Aug 12, 202613w ago Press Release Bullish 7/10 Entry $9.05 to $9.41 Now $7.70 −14.92% ▲ +3.98% +4.42% vs SPY
  8. Jun 1, 202624w ago EFFECT Bearish 5/10 Entry $8.25 to $7.70 Now $7.70 +6.67% ▲ +6.67% +3.92% vs SPY
  9. May 27, 202624w ago S-3/A Neutral 4/10 Entry $8.52 to $8.15 Now $7.70 −9.62% ▼ −4.40% −4.35% vs SPY
  10. May 12, 202626w ago 8-K Neutral 4/10 No price data
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 50m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026